380 related articles for article (PubMed ID: 16927388)
21. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
[TBL] [Abstract][Full Text] [Related]
25. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
26. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
Lu Y; Cai Z; Xiao G; Keller ET; Mizokami A; Yao Z; Roodman GD; Zhang J
Cancer Res; 2007 Apr; 67(8):3646-53. PubMed ID: 17440076
[TBL] [Abstract][Full Text] [Related]
27. Development of an animal model for prostate cancer cell metastasis to adult human bone.
Tsingotjidou AS; Zotalis G; Jackson KR; Sawyers C; Puzas JE; Hicks DG; Reiter R; Lieberman JR
Anticancer Res; 2001; 21(2A):971-8. PubMed ID: 11396190
[TBL] [Abstract][Full Text] [Related]
28. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
29. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
Nicotera TM; Schuster DP; Bourhim M; Chadha K; Klaich G; Corral DA
Prostate; 2009 Sep; 69(12):1270-80. PubMed ID: 19475654
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis of osteoblastic bone metastases from prostate cancer.
Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.
Corey E; Quinn JE; Bladou F; Brown LG; Roudier MP; Brown JM; Buhler KR; Vessella RL
Prostate; 2002 Jun; 52(1):20-33. PubMed ID: 11992617
[TBL] [Abstract][Full Text] [Related]
32. Canine prostate stimulates osteoblast function using the endothelin receptors.
LeRoy BE; Sellers RS; Rosol TJ
Prostate; 2004 May; 59(2):148-56. PubMed ID: 15042615
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
[TBL] [Abstract][Full Text] [Related]
35. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse.
Soos G; Jones RF; Haas GP; Wang CY
Anticancer Res; 1997; 17(6D):4253-8. PubMed ID: 9494517
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
37. PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.
Cumming AP; Hopmans SN; Vukmirović-Popović S; Duivenvoorden WC
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):286-94. PubMed ID: 21826098
[TBL] [Abstract][Full Text] [Related]
38. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
39. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
40. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
Rubin J; Fan X; Rahnert J; Sen B; Hsieh CL; Murphy TC; Nanes MS; Horton LG; Beamer WG; Rosen CJ
Prostate; 2006 Jun; 66(8):789-800. PubMed ID: 16482567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]